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Abstract
Aims/hypothesis—Skeletal muscle accounts for >80% of insulin-stimulated glucose uptake; 
dysfunction of this process underlies insulin resistance and type 2 diabetes. Insulin sensitivity is 
impaired in mice deficient in the double C2 domain β (DOC2B) protein, while whole-body 
overexpression of DOC2B enhances insulin sensitivity. Whether insulin sensitivity in the skeletal 
muscle is affected directly by DOC2B or is secondary to an effect on other tissues is unknown; the 
underlying molecular mechanisms also remain unclear.
Methods—Human skeletal muscle samples from non-diabetic or type 2 diabetic donors were 
evaluated for loss of DOC2B during diabetes development. For in vivo analysis, new doxycycline-
inducible skeletal-muscle-specific Doc2b-overexpressing mice fed standard or high-fat diets were 
evaluated for insulin and glucose tolerance, and insulin-stimulated GLUT4 accumulation at the 
plasma membrane (PM). For in vitro analyses, a DOC2B-overexpressing L6-GLUT4-myc 
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myoblast/myotube culture system was coupled with an insulin resistance paradigm. Biochemical 
and molecular biology methods such as site-directed mutagenesis, co-immunoprecipitation and 
mass spectrometry were used to identify the molecular mechanisms linking insulin stimulation to 
DOC2B.
Results—We identified loss of DOC2B (55% reduction in RNA and 40% reduction in protein) in 
the skeletal muscle of human donors with type 2 diabetes. Furthermore, inducible enrichment of 
DOC2B in skeletal muscle of transgenic mice enhanced whole-body glucose tolerance (AUC 
decreased by 25% for female mice) and peripheral insulin sensitivity (area over the curve 
increased by 20% and 26% for female and male mice, respectively) in vivo, underpinned by 
enhanced insulin-stimulated GLUT4 accumulation at the PM. Moreover, DOC2B enrichment in 
skeletal muscle protected mice from high-fat-diet-induced peripheral insulin resistance, despite the 
persistence of obesity. In L6-GLUT4-myc myoblasts, DOC2B enrichment was sufficient to 
preserve normal insulin-stimulated GLUT4 accumulation at the PM in cells exposed to 
diabetogenic stimuli. We further identified that DOC2B is phosphorylated on insulin stimulation, 
enhancing its interaction with a microtubule motor protein, kinesin light chain 1 (KLC1). Mutation 
of Y301 in DOC2B blocked the insulin-stimulated phosphorylation of DOC2B and interaction 
with KLC1, and it blunted the ability of DOC2B to enhance insulin-stimulated GLUT4 
accumulation at the PM.
Conclusions/interpretation—These results suggest that DOC2B collaborates with KLC1 to 
regulate insulin-stimulated GLUT4 accumulation at the PM and regulates insulin sensitivity. Our 
observation provides a basis for pursuing DOC2B as a novel drug target in the muscle to prevent/
treat type 2 diabetes.
Keywords
DOC2B; Glucose homeostasis; GLUT4; Insulin sensitivity; KLC1; Obesity; Skeletal muscle; Type 
2 diabetes
Introduction
Insulin resistance, characterised by a lack of target tissue response to insulin stimulation, is a 
key factor in progression towards the metabolic syndrome and type 2 diabetes [1]. Skeletal 
muscle has been reported to account for 80–90% of insulin-stimulated glucose uptake [2], 
with uptake facilitated by the insulin-responsive glucose transporter GLUT4. As GLUT4 
vesicles must translocate from the cell interior to the plasma membrane (PM) to facilitate 
uptake [3], strategies to promote GLUT4 translocation and improve insulin sensitivity in 
skeletal muscle are in demand as a means to prevent and treat type 2 diabetes.
Double C2 domain β (DOC2B) is a calcium-sensitive protein that positively regulates the 
insulin-stimulated translocation of GLUT4 to the PM in adipocytes [4]. In addition, DOC2B 
enhances insulin secretion in pancreatic beta cells [5, 6] and increases spontaneous and 
asynchronous neurotransmitter release from neuronal cells [7, 8]. Doc2b-knockout mice 
show insulin resistance and impaired glucose uptake in skeletal muscle [9, 10] and ‘global’ 
overexpression of Doc2b enhances peripheral insulin sensitivity [11]. While an association 
between DOC2B deficiency in skeletal muscle and diabetes susceptibility exists in rodents 
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[12], it is not known whether skeletal muscle DOC2B is associated with human type 2 
diabetes. Furthermore, it is not known whether skeletal-muscle-specific enrichment of 
DOC2B is sufficient to enhance whole-body insulin sensitivity.
While it is generally agreed that DOC2B is vital to insulin-stimulated GLUT4 vesicle 
translocation [13], the precise mechanism(s) involving DOC2B remain unresolved. GLUT4 
translocation starts with the binding of extracellular insulin to the insulin receptors (INSRs) 
on the skeletal muscle PM, which activates a phosphorylation-dependent intracellular 
signalling cascade. This cascade triggers the intracellular GLUT4-containing vesicles to 
translocate to the PM, where the vesicles are docked and fused via soluble N-
ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE) proteins [13, 
14], including two target-associated (t)-SNARE proteins, syntaxin 4 (STX4) and 
synaptosome-associated protein 23 (SNAP23), as well as one vesicle-associated (v)-SNARE 
protein, VAMP2 [15–17]. Vesicle fusion promotes the integration of GLUT4 into the PM, 
which facilitates glucose uptake. Several reports show that DOC2B is a soluble protein and 
can exist in the cytosol, consistent with DOC2B having no transmembrane domain [4, 18, 
19]. DOC2B is speculated to regulate insulin-stimulated GLUT4 translocation via insulin-
induced DOC2B translocation from the cytosol to the PM, where the target-associated 
SNARE (t-SNARE) proteins reside [4, 18, 20, 21]. At the PM, insulin stimulation increases 
DOC2B binding to phosphorylated syntaxin binding protein (STXBP)3, increasing SNARE 
complex formation [9, 11, 22]. To understand how DOC2B regulates insulin-stimulated 
glucose uptake, it is crucial to uncover the mechanism linking the insulin signal to DOC2B 
response.
DOC2B is a ubiquitously expressed protein [23–25] that harbours a Munc13-interacting 
domain (MID) and two sequential C2 domains, termed C2A and C2B [21]. Recent 
phosphor-proteomic studies identified several putative DOC2B phosphorylation sites within 
the C2B domain [26–28]. However, whether insulin stimulates DOC2B phosphorylation 
remains unknown. In addition, although several studies report DOC2B interaction partners, 
such as dynein light chain Tctex-type 1 (DYNLT1) in adipocytes [29, 30] and STXBP1 and 
STXBP3 in pancreatic beta cells [31], most of these DOC2B interaction partners are 
components of the exocytic machinery near the PM. Cytoplasmic interaction partners of 
DOC2B remain unexplored, particularly in skeletal muscle. Herein, we used human skeletal 
muscle samples, an inducible skeletal-muscle-specific Doc2b-overexpressing mouse model, 
and a myoblast/myotube culture system to address the relationship between DOC2B and 
insulin sensitivity.
Methods
Materials, antibodies and plasmid constructs
All antibodies were validated using specific blocking peptide and titrated before 
experiments. For detailed source and dilution of antibody, please see the electronic 
supplementary material (ESM) Methods. The green fluorescent protein (GFP)-tagged 
Doc2b-GFP and C2AB-GFP plasmids were kindly provided by U. Ashery (Tel-Aviv 
University, Tel-Aviv, Israel) as described previously [1]. hDOC2B-GFP in the pEGFP-N2 
backbone was constructed by Genescripts (Piscataway, NJ, USA). Y301 of Doc2b-GFP and 
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hDOC2B-GFP was mutated to F301 by Genescripts. Adenovirus Ad-DOC2B-wild type 
(WT), Ad-Y301F-GFP or Ad-GFP were generated by insertion of the hDOC2B-GFP, 
hDOC2B-Y301F-GFP fusion gene or GFP alone into the pAd5CMVmpA adenoviral vector 
by ViraQuest (North Liberty, IA, USA). Adenovirus Ad-DOC2B alone was made similarly 
and virus packaged with GFP (See ESM Methods).
Human skeletal muscle biopsies
Sixteen skeletal muscle samples from the leg muscles of non-diabetic and type 2 diabetic 
donors were purchased from the National Disease Research Interchange (NDRI). The 
donors were white men and women between 45 and 78 years old (ESM Table 1). The 
procurement of human skeletal muscle biopsies from NDRI was approved by the 
Institutional Review Board at University of Pennsylvania. The participants gave informed 
consent. The investigation was carried out in accordance with the principles of the 
Declaration of Helsinki as revised in 2008. The samples were snap-frozen and kept at 80°C 
until mRNA and protein extraction.
Animals and in vivo experiments
Animals were maintained in ventilated cages with a 12 h light/dark cycle and access to food 
and water ad libitum under protocols approved by the City of Hope or Indiana University 
School of Medicine Institutional Animal Care and Use Committees and in accordance with 
Guidelines for the Use and Care of Laboratory Animals as well as other applicable local and 
national regulations. Rat Doc2b cDNA was subcloned into the 5′ Pme1 and 3′ BamH1 
restriction sites in the pTRE-IRES-nGFP vector provided by S. Afelik and J. Jenssen 
(Cleveland Clinic, Cleveland, OH, USA) and microinjected into B6 oocytes to produce a 
tetracycline-responsive element (TRE)-Doc2b−/+ founder, as described previously [32]. 
Skeletal-muscle-specific muscle creatine kinase (Mck [also known as Ckm]) promoter 
reverse tetracycline transactivator (rtTA) mice (Mck-rtTA−/+) were purchased from the 
Jackson Laboratory (Bar Harbor, ME, USA). TREDoc2b−/+ offspring crossed to Mck-rtTA
−/+
 mice produced doxycycline (Dox)-inducible skeletal muscle-selective expression in the 
double transgenic offspring (skmDoc2b-dTg) mice. Male and female B6 skmDoc2b-dTg 
mice (4–5 months old) were administered Dox-treated (2 mg/ml) or standard drinking water 
for 3 weeks to induce Doc2b overexpression prior to phenotyping assessment. A high-fat 
diet (HFD) containing 60% of energy from fat, with or without Dox, (catalogue numbers 
S6470 and S3282, respectively, Bio-Serv, Flemington, NJ, USA), was fed to 7–8-week-old 
male mice for 4–5 weeks to induce insulin resistance prior to phenotyping and body 
composition assessment. (See ESM Methods).
Sample size Littermate mice of the same age were randomised to different subgroups of 6–
10 animals. The western blot images are representative of at least three independent 
experiments. The independent cell culture experiments were conducted using independent 
passages of cells. The sample size was determined based on a similar study of whole-body 
Doc2b overexpression in mice [11]. Data falling within the mean ± 2 SD were included in 
the final statistical analysis.
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Intraperitoneal glucose tolerance test, insulin tolerance test and serum analysis
Mice were fasted 6 h (08:00–14:00 hours) before i.p. glucose tolerance tests (IPGTTs) and 
i.p. insulin tolerance tests (IPITTs), which were performed as described previously [9]. The 
mice were killed at 24–26 weeks old and serum and tissues were collected. Serum insulin 
and glucagon levels were measured via radioimmunoassay (Millipore, Burlington, MA, 
USA).
Cell culture
Authentic L6-GLUT4-myc myoblasts, which were free from mycoplasma contamination, 
were purchased from Kerafast (Boston, MA, USA) and grown as monolayers in MEM-α 
medium supplemented with 10% FBS (vol./vol.) and 1% (vol./vol.) antibiotic–antimycotic 
solution (Thermo Fisher, Waltham, MA, USA), as described previously [33]. L6-GLUT4-
myc myoblasts were differentiated into myotubes by seeding them at 1×104 cells/ml in 
MEM-α medium containing 2% FBS (vol./vol.) for 7 days. For all studies involving the 
insulin resistance, as experimentally induced in vitro (InsRes) paradigm, L6-GLUT4-myc 
myoblasts (90% confluence) or myotubes were preincubated in medium containing 5 nmol/l 
insulin for 12 h to simulate chronic insulinaemia [34, 35]. Cells were then washed and 
incubated in serum-free MEM-α medium for 40 min immediately prior to acute insulin 
stimulation (100 nmol/l) for 5 min for assessment of phosphorylation or for 20 min for cell-
surface GLUT4-Myc detection.
RNA extraction and quantitative real-time PCR analysis
RNA was extracted using TRI Reagent according to the manufacturer’s protocol 
(MilliporeSigma, St Louis, MO, USA). Synthesis of cDNA was performed using the iScript 
cDNA synthesis kit, as described by the manufacturer (Bio-Rad, Hercules, CA, USA). Real-
time PCR was carried out for 40 cycles using the iCycler (Bio-Rad). Each cycle was run at 
95°C for 15 s, 60°C for 30 s and 72°C for 30 s. See the ESM Methods and ESM Table 2 for 
the primer sequences and further details.
Cell-surface GLUT4-myc detection
Cell-surface GLUT4-myc detection was performed as previously described [34, 36]. See 
ESM Methods.
2-Deoxyglucose uptake
The 2-deoxyglucose (2-DG) uptake assay was performed as described previously [36]. See 
ESM Methods.
Co-immunoprecipitation and immunoblotting
The cells were harvested into 1% NP-40 (vol./vol.) lysis buffer and 2.5 mg of the lysate was 
immediately used for immunoprecipitation by overnight incubation with 30 μl of rabbit 
polyclonal anti-GFP antibody conjugated to Sepharose beads. Co-immunoprecipitation from 
mouse skeletal muscle tissue was performed similarly, using 4 mg of tissue homogenate 
combined with anti-Myc-conjugated beads (Thermo Fisher, Waltham, MA, USA [catalogue 
number 20168]). The immunoprecipitated proteins were washed three times with lysis buffer 
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and boiled in Laemmli sample buffer containing fresh dithiothreitol. The proteins in the cell 
lysates were resolved using 10–12% SDS-PAGE (wt/vol.) and transferred to polyvinylidene 
difluoride (PVDF) membranes for immunoblotting. See the ESM Methods.
Subcellular fractionation of skeletal muscle
The subcellular fractionation of skeletal muscle was performed as described previously [9, 
37]. See the ESM Methods.
Statistical analysis
All data were evaluated for statistical significance using a paired two-tailed Student’s t test 
for comparison of two groups or ANOVA for more than two groups, using GraphPad Prism 
Version 7.0 (GraphPad software, La Jolla, CA, USA). Data are expressed as the average ± 
SEM.
Results
DOC2B abundance is decreased in type 2 diabetic human skeletal muscle and insulin-
resistant muscle cells
Whole-body Doc2b-knockout mice display peripheral insulin resistance in vivo and 
defective insulin-stimulated glucose uptake into skeletal muscle [9]; therefore, we tested 
whether DOC2B is deficient in human skeletal muscle from type 2 diabetic individuals 
compared with non-diabetic control individuals (ESM Table 1) using real-time PCR and 
immunoblotting analysis. The DOC2B mRNA level was reduced by 55% (Fig. 1a) and the 
DOC2B protein level was reduced by 40% (Fig. 1b) in human skeletal muscle samples from 
type 2 diabetic individuals compared with non-diabetic individuals. To determine whether 
the decreased DOC2B level in type 2 diabetic skeletal muscle was caused by insulin 
resistance prior to type 2 diabetes/hyperglycaemia or is a consequence of type 2 diabetes/
hyperglycaemia, we examined the DOC2B mRNA and DOC2B protein levels in L6-
GLUT4-myc myoblasts subjected to a well-established in vitro paradigm to induce InsRes 
[34, 35]. The InsRes paradigm attenuated insulin-stimulated GLUT4 accumulation at the 
PM, as reported previously [34, 35] (Fig. 1c), and decreased the stimulation index (insulin-
stimulated/basal GLUT4 levels at the PM) (Fig. 1d). Concomitant with these InsRes-induced 
changes, Doc2b mRNA was reduced by 30% (Fig. 1e) and DOC2B protein was decreased 
by 20% (Fig. 1f) in InsRes-exposed L6-GLUT4-myc myoblasts compared with control cells. 
These results suggest DOC2B may become reduced during insulin resistance prior to type 2 
diabetes and hyperglycaemia.
DOC2B enrichment protects myotubes and myoblasts from dysfunction under insulin 
resistance conditions
Given that the global Doc2b-overexpressing mice showed enhanced insulin sensitivity, we 
next questioned whether DOC2B enrichment could prevent InsRes in skeletal myotubes. 
Myotubes exhibit a physiological glucose uptake response similar to that of primary tissue, 
while myoblasts are suitable for GLUT4 accumulation analysis and biochemical assays 
requiring large amounts of protein. Differentiated L6-GLUT4-myc myotubes were 
adenovirally transduced to overexpress DOC2B protein, and a multiplicity of infection 
Zhang et al. Page 6
Diabetologia. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(MOI) of 200 was sufficient for enrichment in ~80% of myotubes, as detected by GFP 
expression (adenovirus packaged with GFP; Fig. 2a,b). Under control conditions, insulin 
stimulated glucose uptake to a level more than twofold that of basal levels (Fig. 2c) as has 
been reported previously [36], while InsRes conditions blocked the insulin response (Fig. 
2c). Notably, DOC2B-overexpressing myotubes resisted the InsRes-induced attenuation of 
insulin-stimulated glucose uptake (Fig. 2c). Consistently, InsRes conditions blocked insulin-
stimulated GLUT4 accumulation at the PM in myoblasts (Fig. 2d). Furthermore, DOC2B-
GFP-overexpressing myoblasts resisted the InsRes-induced attenuation of insulin-stimulated 
GLUT4 accumulation at the PM (Fig. 2d). DOC2B-overexpression also boosted insulin-
stimulated glucose uptake and GLUT4 accumulation at the PM under control conditions 
(Fig. 2c,d). These data indicate that DOC2B protects against InsRes-mediated impairment of 
glucose uptake, potentially by preventing the loss of insulin-induced GLUT4 vesicle 
translocation.
Inducible skeletal-muscle-specific DOC2B-expressing mice demonstrate enhanced 
glucose tolerance, insulin sensitivity and skeletal muscle GLUT4 accumulation at the PM
To determine whether skeletal muscle-specific enrichment of DOC2B is sufficient to 
promote insulin sensitivity in vivo, we generated a Dox-inducible skeletal-muscle-specific 
double transgenic mouse model (skmDoc2b-dTg) expressing DOC2B with a C-terminal 
Myc tag (Fig. 3a). Using an anti-Myc antibody, we detected the transgene-encoded DOC2B-
Myc protein in the skeletal muscle of Dox-treated skmDoc2b-dTg mice; DOC2B-Myc was 
not present in non-Dox-treated skmDoc2b-dTg mice, Dox-treated Mck-rtTA+/− mice or WT 
control mice (Fig. 3b). The Doc2b mRNA abundance in skeletal muscle was ~2–3-fold 
higher in Dox-induced skmDoc2b-dTg mice than non-Dox-treated skmDoc2b-dTg, Dox-
treated TRE-Doc2b+/−and Dox-treated Mck-rtTA+/− control mice (Fig. 3c). However, the 
Doc2b mRNA level in the heart was unchanged, confirming the skeletal muscle-specificity 
of the transgene expression (Fig. 3d). This is consistent with a prior report that Mck-rtTA+/− 
regulates protein overexpression in skeletal muscle but not heart muscle [38]. Further, 
DOC2B upregulation was not associated with dwarfism or obesity, and did not cause energy-
intake restriction or hyperphagia, as evidenced by body fat, body weight and food intake 
measures (ESM Fig. 1a,b). In addition, no changes in the respiratory exchange ratio or 
activity level (ESM Fig. 1c,d) were observed.
Next, we evaluated insulin-stimulated GLUT4 accumulation at the PM in the skmDoc2bdTg 
mice. Insulin stimulation increased the accumulation of GLUT4 in the sarcolemmal/t-tubule 
fraction of mouse hindlimb muscle by 1.5 fold in control male mice (non-Dox-treated 
skmDoc2b-dTg), consistent with prior reports [9, 37]; Dox-treated skmDoc2b-dTg male 
mice showed significantly more insulin-stimulated GLUT4 accumulation in this plasma-
membrane-like fraction compared with controls (Fig. 3e). No differences in insulin-
stimulated GLUT4 accumulation were seen under basal conditions in the Dox-induced 
skmDoc2b-dTg muscle, and total GLUT4 protein expression levels in whole-cell lysates 
were similar in Dox-induced skmDoc2b-dTg and control mice (Fig. 3f). These results are 
consistent with our findings using DOC2B-overexpressing L6-GLUT4-myc myoblasts.
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As enhanced GLUT4 accumulation at the PM is correlated with insulin sensitivity and 
glucose tolerance, skmDoc2b-dTg mice were subjected to IPGTT and IPITT. Because global 
overexpression of DOC2B enhanced muscle insulin sensitivity even without induction of 
insulin resistance [11], IPGTT and IPITT were first performed in skmDoc2b-dTg mice 
without induction of insulin resistance. Both female and male Doc2B-overexpressing mice 
showed significantly enhanced insulin sensitivity in the IPITT with AOC increased by 20% 
and 26% for female and male mice respectively in vivo (Fig. 4a–d). Female Doc2b-
overexpressing mice exhibited an improvement in both the rate and extent of the reduction in 
glycaemia in the IPGTT compared with the non-Dox-treated mice with AUC decreased by 
25% (Fig. 4e,f); the differences for males did not reach statistical significance (Fig. 4g,h; 
p=0.07). These results with the male mice are consistent with findings in whole-body Stx4-
overexpressing [39] or Doc2boverexpressing [11] mice in this age range. Control TRE-
Doc2b+/− and Mck-rtTA+/− mice showed no response to Dox in the IPITT or IPGTT (ESM 
Fig. 2a–d). DOC2B enrichment in muscle had no prominent effects on systemic glucose 
metabolism, as determined by similar levels of serum insulin, glucagon, cholesterol and 
NEFA (ESM Table 3). In addition, no significant differences in body weight or organ 
weights were detected between the Dox-treated and untreated skmDoc2b-Tg mice (ESM 
Table 4). Together, these results suggest that skeletal-muscle-specific DOC2B enrichment 
can enhance whole-body glucose homeostasis and peripheral insulin sensitivity, consistent 
with its role in regulating insulin-stimulated GLUT4 translocation.
SkmDoc2b-dTg mice are protected from HFD-induced insulin resistance
To determine whether skeletal muscle-specific enrichment of DOC2B could protect against 
insulin resistance in vivo, we placed male skmDoc2b-dTg mice on an HFD for 4 weeks; this 
has been shown to induce skeletal muscle insulin resistance [40–43]. IPITT and IPGTT 
analyses show that HFD induces insulin resistance and glucose intolerance in control mice 
(non-Dox-treated skmDoc2b-dTg) compared with chow-fed mice (Fig. 5a, ESM Fig. 3). 
Skeletal-muscle-specific expression of DOC2B completely blocked the effects of the HFD 
on insulin sensitivity (Fig. 5a). These DOC2B-associated improvements in peripheral insulin 
sensitivity occurred despite the obesity resulting from elevated energy intake in the mice fed 
HFD, with and without Dox treatment (Fig. 5b,c; ESM Fig. 3). However, DOC2B 
enrichment in skeletal muscle did not protect against the whole-body glucose intolerance 
caused by the HFD, likely due to the beta cell dysfunction caused by this diet. Overall, these 
data indicate that DOC2B enrichment in skeletal muscle protects against HFD-induced 
insulin resistance in vivo.
Insulin stimulation phosphorylates DOC2B and augments its association with KLC1
Several groups have speculated that DOC2B in the cytoplasm responds to insulin stimulation 
and translocates to the PM [4, 20], where it positively regulates STX4-based SNARE 
complex formation to promote GLUT4 vesicle docking/fusion at the PM [6, 9, 11, 22]; this 
mechanism could underlie the enhancement by DOC2B of peripheral insulin sensitivity and 
glucose tolerance. However, the molecular mechanism linking insulin action and DOC2B 
translocation is not known. Because the canonical insulin-signalling pathways involve 
multiple phosphorylation events [44–46], we hypothesised that insulin stimulation might 
phosphorylate DOC2B to promote insulin-stimulated GLUT4 translocation. Towards this, 
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we immunoprecipitated DOC2B-Myc from skmDoc2b-dTg hindlimb muscle homogenates 
prepared from mice injected with saline (154 mmol/l NaCl) or insulin and immunoblotted 
using the canonical anti-tyrosine phosphorylation antibody PY20 [47, 48]. Insulin-
stimulated muscle showed a 1.6-fold increase in tyrosine-phosphorylated DOC2B-Myc 
compared with saline-injected homogenates (Fig. 6a). Similarly, L6-GLUT4-myc myoblasts 
were transfected to express GFP or DOC2B-GFP and treated with insulin or pervanadate 
(pV, a tyrosine-selective phosphatase inhibitor [22]) for 5 min; phospho-enrichment beads 
captured a significant increase in phosphorylated DOC2B-GFP (molecular mass 75 kDa) in 
the insulin-stimulated and pV-treated cells (Fig. 6b), as detected using an anti-GFP antibody. 
The abundance of free GFP (molecular mass 25 kDa) in the input and its absence in the 
eluate confirmed the specificity of DOC2B-GFP binding to the phosphoenrichment beads. 
The insulin- or pV-induced phosphorylation of the INSR beta subunit was used as a control 
for the action of insulin and pV. Equal amounts of DOC2B-GFP were loaded on the 
phospho-enrichment beads. The pV-stimulated detection of tyrosine phosphorylation of 
DOC2B-GFP was further confirmed by immunoprecipitation using the PY20 antibody 
(ESM Fig. 4). These results suggest that insulin stimulation phosphorylates DOC2B, 
probably on one or more tyrosine residues.
Next, mass spectrometry analysis was used to identify potential phospho-DOC2B binding 
partners in the cytoplasm. L6-GLUT4-myc myoblasts were transfected to express DOC2B-
GFP or GFP and treated with insulin or pV; the resulting cell lysates were incubated with 
commercial anti-GFP-conjugated Sepharose beads to capture potential interacting partners. 
Proteins bound to the beads were subjected to SDS-PAGE. Visible differences were detected 
in the protein profile from 50 to 150 kDa; this region was excised for mass spectrometry 
analysis (ESM Fig. 5a). Of 173 proteins identified with at least three unique peptides, the 14 
proteins detected selectively in insulin- or pV-treated DOC2B-overexpressing lysates, but 
not in GFP-overexpressing lysates, are summarised in ESM Table 5. Kinesin light chain 1 
(KLC1), which also shows enhanced binding to DOC2B under insulin- or pV-treated 
conditions compared with the basal conditions, was chosen based on a prior report showing 
that dominant negative mutants of KLC1 reduce insulin-stimulated GLUT4 translocation 
[49]. The unique peptide sequence of KLC1 identified by mass spectrometry covered 12% 
of KLC1, ruling out the possibility of false identification (ESM Fig. 5b). By using GFP 
antibody-conjugated Sepharose beads, which capture both free GFP and DOC2B-GFP, 
KLC1 was found to co-immunoprecipitated with DOC2B-GFP but not GFP; pV-treated 
lysates showed an increased level of KLC1 associated with DOC2B-GFP (Fig. 6c). 
Consistent with DOC2B phosphorylation at 5 min, insulin stimulation for 5 min 
significantly increased the association of DOC2B-GFP with KLC1 (Fig. 6d). These findings 
suggest that insulin-stimulated DOC2B phosphorylation enhances the DOC2B–KLC1 
interaction.
DOC2B Y301F mutation disrupts the DOC2B–KLC1 association and blocks the protective 
effect of DOC2B enrichment
To investigate the molecular basis of the insulin-regulated DOC2B–KLC1 interaction, we 
sought to identify the site of insulin-stimulated tyrosine phosphorylation on DOC2B. To 
focus our search on the minimal DOC2B domain(s) necessary to confer insulin-stimulated 
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GLUT4 translocation, an N-terminal truncation (DOC2B MID domain was deleted) with a 
C-terminal GFP tag (C2AB-GFP) was generated (Fig. 7a). Like full-length DOC2B-GFP, 
C2AB-GFP conferred enhanced insulin-stimulated GLUT4 accumulation at the PM, relative 
to GFP alone (Fig. 7b). Importantly, C2AB-GFP also protected against the negative effects 
of InsRes on GLUT4 accumulation at the PM, similar to full-length DOC2B (Fig. 7b). The 
ability of C2AB to fully recapitulate the effects of full-length DOC2B suggested that it 
probably contained the site(s) of insulin-stimulated phosphorylation on DOC2B. Although 
three tyrosine residues located within the C2B domain of DOC2B, Y301, Y305 and Y309, 
are 100% conserved in rat mouseand human, solvent accessibility prediction analyses 
indicated that Y301 is highly solvent exposed and located in an unstructured loop region, 
which is ideal for kinase accessibility and modification [50] (Fig. 7c); the other two sites, 
Y305 and Y309, are localised in beta sheets and considered less accessible.
To evaluate the importance of Y301 to the insulin-stimulated interaction of DOC2B with 
KLC1, a conservative substitution (Y to F) was made to Y301 on DOC2B-GFP. The insulin-
stimulated phosphorylation of DOC2B-GFP was blocked by the Y301F mutation (Fig. 8a). 
Moreover, KLC1 was poorly co-immunoprecipitated with DOC2B-GFP-Y301F (Fig. 8b). In 
contrast to the protective effect of WT DOC2B, the Y301F mutant did not protect cells from 
the negative effects of InsRes on GLUT4 accumulation at the PM (Fig. 8c) or 2-DG uptake 
(Fig. 8d). Hence, our data reveal a new mechanism by which insulin stimulates 
phosphorylation of DOC2B, brokering its interaction with KLC1, and that this mechanism is 
required for DOC2B enrichment to protect cells against InsRes stimuli.
Discussion
We now show that DOC2B is reduced in the skeletal muscle of human type 2 diabetic 
donors and that this DOC2B reduction can be recapitulated by inducing insulin resistance in 
an in vitro InsRes model. Remarkably, this study also shows that DOC2B enrichment in 
skeletal muscle is sufficient to improve whole-body insulin sensitivity and glucose tolerance 
and to protect against HFD-induced insulin resistance in vivo. Moreover, DOC2B 
enrichment in skeletal muscle cells can counter the negative effects of InsRes on GLUT4 
accumulation at the PM and glucose uptake at the cellular level. As we observed no effect of 
DOC2B enrichment on serum insulin, glucagon, cholesterol or NEFA levels, we reason that 
the enhanced whole-body glucose tolerance is primarily due to improved muscle insulin 
sensitivity, increasing the rate of glucose clearance from the blood. These data are also 
consistent with previous findings that DOC2B positively regulates GLUT4 translocation in 
adipocytes, and that Doc2b-knockout mice have impaired insulin sensitivity and muscle 
glucose uptake [9, 10], whereas mice with global enrichment of DOC2B exhibit enhanced 
muscle insulin sensitivity [11]. Thus, we have shown that enrichment of DOC2B solely in 
skeletal muscle is sufficient to mimic the effects of whole-body overexpression.
This study also advances our knowledge of the mechanisms linking DOC2B to insulin action 
in the skeletal muscle. We report, for the first time, that insulin stimulation of muscle cells 
induces DOC2B phosphorylation, probably at one or more tyrosine residues. Our results 
further implicate DOC2B-Y301 phosphorylation in regulating insulin action in skeletal 
muscle. However, the DOC2B sequence has multiple potential phosphorylation sites. 
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Previous proteomic studies have identified a variety of phosphorylation sites on DOC2B, 
such as Y301 and Y305 in Jurkat cells [28], Y309 in untreated human immortalised 
myelogenous leukaemia cells [27] and S411 in untreated human breast cancer tissues [51]. 
Although we provide evidence for DOC2B phosphorylation, the kinase is unknown because 
of the complexity of the kinase–substrate relationship in the insulin-signalling pathway. It is 
possible that one of the insulin pathway kinases, perhaps even the INSR itself, is responsible 
for the insulin-stimulated phosphorylation of DOC2B (www.phosphonet.ca/kinasepredictor). 
This awaits further investigation. Overall, these findings imply that DOC2B may be 
phosphorylated in a cell-type- and stimulation-dependent manner.
Our mechanistic analysis of DOC2B phosphorylation also led us to identify a DOC2B 
binding partner, KLC1, which is a cytoskeletal motor protein with a proposed role in 
protein/vesicle translocation. Tyrosine phosphorylation enhances the DOC2B interaction 
with KLC1, suggesting that DOC2B–KLC1 interaction is important for DOC2B enrichment 
to enhance GLUT4 translocation; however, the protein domains involved in this interaction 
are unknown. No Src homology 2 (SH2)/pTyr-binding (PTB) domains are reported to exist 
in either DOC2B or KLC1, so the enhanced interaction between phospho-DOC2B and 
KLC1 may occur through another mechanism, such as conformational change. Indeed, 
phosphorylation events often induce conformational changes, and DOC2B is a known 
scaffolding platform for several exocytosis regulatory proteins [31]. Conformational changes 
to DOC2B could also affect SNARE assembly, promoting GLUT4 translocation and glucose 
uptake. Alternatively, there are multiple tetratricopeptide repeats (TPRs) in KLC1, which are 
involved in binding to a variety of factors [52], and it is possible that DOC2B binds to the 
TPR domain(s) of KLC1. Hence, while we have identified the phospho-DOC2B interaction 
with KLC1 and shown it to be important for glucose uptake, future studies will be required 
to explore these and other potential mechanisms.
This study advances our understanding of how DOC2B responds to insulin stimulation to 
regulate GLUT4 vesicle translocation. Although DOC2B is important for assembly of the 
SNARE machinery at the PM [53], it has also been shown to exist in the cytosolic 
compartment and to translocate to the PM in response to insulin stimulation [4]. Indeed, 
DOC2B may play both roles by virtue of dual cellular compartmentalisation—existing in 
two pools, one at the PM, the other in the cytosolic space. We and others have speculated 
that SNARE assembly occurs in parallel with GLUT4 vesicle translocation, orchestrating the 
preparation of the plasma-membrane-localised t-SNARE proteins for the arrival of the 
vesicle-associated SNARE (v-SNARE)-loaded GLUT4 vesicle for seamless vesicle docking 
and fusion events [22, 54]. KLC1 is also localised to the cytoplasm under basal conditions, 
consistent with its role in microtubule-based GLUT4 vesicle trafficking [55], and hence 
insulin-stimulated enhancement of DOC2B–KLC1 interaction may represent an early event 
in the process of GLUT4 vesicle translocation to the PM. This is consistent with a prior 
report showing that inhibition of the microtubule motor protein kinesin impairs insulin-
stimulated GLUT4 translocation [56] and microtubule-depolymerising agents (nocodazole, 
colchicine and vinblastine) inhibit insulin-stimulated glucose uptake and GLUT4 
translocation [57]. Hence, in addition to its previously described role in activating SNARE 
complexes at the PM, we demonstrate herein a mechanism by which DOC2B impacts 
insulin-stimulated GLUT4 vesicle translocation via collaboration with the microtubule 
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network protein KLC1. Our finding that this interaction is important to the protective role of 
DOC2B against insulin resistance will be important to future efforts in therapeutic design.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research in context
What is already known about this subject?
• Doc2b-knockout mice show impaired insulin sensitivity and skeletal muscle 
glucose uptake
• Mice overexpressing Doc2b in multiple tissues, including pancreas, fat and 
skeletal muscle, show enhanced peripheral insulin sensitivity and whole-body 
glucose tolerance
• DOC2B facilitates insulin-stimulated GLUT4 translocation in adipocytes by 
regulating the process of SNARE complex formation
What is the key question?
• Is skeletal muscle-specific expression of DOC2B sufficient to regulate insulin 
sensitivity and what are the early molecular mechanisms underlying the link 
between insulin stimulation and DOC2B function?
What are the new findings?
• Inducible DOC2B enrichment solely in skeletal muscle enhances in vivo 
peripheral insulin sensitivity and promotes GLUT4 accumulation under 
standard conditions. Even after high-fat-diet-induced obesity, DOC2B 
enrichment in skeletal muscle preserves insulin sensitivity
• DOC2B enrichment in myotubes and myoblasts protectsagainst dysfunction 
mediated by diabetogenic stimuli
• Insulin stimulation phosphorylates DOC2Bat Y301 and enhances its 
interaction with KLCl; the DOC2B-KLC1 interaction mediates insulin-
stimulated GLUT4 translocation
How might this impact on clinical practice in the foreseeable future?
• Our observations provide a compelling basis for pursuing DOC2B as a novel 
drug target in skeletal muscle to prevent/treat type 2 diabetes
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Fig. 1. 
DOC2B expression is attenuated in the skeletal muscle of human type 2 diabetic donors and 
insulin-resistant L6-GLUT4-myc muscle cells. (a, b) Real-time PCR and western blot 
analyses of DOC2B mRNA (a) (n=3 for non-diabetic donors and n=4 for donors with type 2 
diabetes) and DOC2B protein levels (b) (n=8 for non-diabetic donors and n=8 for donors 
with type 2 diabetes) in human skeletal muscle samples. The relative mRNA or protein level 
was calculated by normalising to HPRT. (c) PM GLUT4 level in control and InsRes L6-
GLUT4-myc cells under basal conditions (−) and after 100 nmol/l insulin stimulation for 20 
min (+). The immunofluorescence intensity of cell-surface GLUT4 was normalised to the 
nucleic acid staining dye SYTO 60. (d) The stimulation index was calculated as a ratio of 
the relative GLUT4 value in (c) after insulin stimulation, divided by relative GLUT4 value 
without insulin stimulation, under Ctrl or InsRes conditions. (e, f) Real-time PCR of Doc2b 
mRNA levels (e) and western blot analysis of DOC2B protein levels (f) in control and 
InsRes L6-GLUT4-myc cells. For (c–f) n=3. *p<0.05 vs ND/Ctrl, or as otherwise shown. 
Dashed vertical lines indicate splicing of lanes within the same gel exposure. Ctrl, control; 
HPRT, hypoxanthine guanine phosphoribosyl transferase; Ins, insulin; ND, non-diabetic 
donor; T2D, type 2 diabetic donor
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Fig. 2. 
DOC2B enrichment preserves insulin-stimulated glucose uptake via GLUT4 translocation in 
L6-GLUT4-myc myotubes exposed to insulin resistance stimuli. (a, b) Expression of 
DOC2B and transduction efficiency for L6-GLUT4-myc myoblasts that were differentiated 
into myotubes and transduced with Ad-DOC2B or vector control adenoviral particles at 
multiple MOIs, as shown by (a) western blot analysis and (b) evaluation of GFP 
fluorescence (from viral packaging); scale bar, 400 μm. White arrows denoting DOC2B-
transduced myotubes in the fluorescence image correspond to the same myotubes seen in the 
bright field image. (c) 2-DG uptake in myotubes incubated under control or InsRes 
conditions. The myotubes were transduced with Ad-GFP or Ad-DOC2B before induction of 
InsRes conditions. (d) Surface GLUT4 levels in L6-GLUT4-myc myoblasts transfected with 
DOC2B-GFP or control GFP plasmid DNA, incubated under control or InsRes conditions 
and measured in response to stimulatory insulin. For (c) and (d), the cells were stimulated 
with 100 nmol/l insulin to induce 2-DG uptake or GLUT4 translocation. The 
immunofluorescence intensity of cell-surface GLUT4 was normalised to the nucleic acid 
staining dye SYTO 60. n=3. *p<0.05, **p<0.01, ***p<0.001 as shown. Ctrl, control; Ins, 
insulin
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Fig. 3. 
Generation of skmDoc2b-dTg mice. (a) Mice containing a Myc-tagged Doc2b transgene 
under control of the Dox-inducible TRE-Doc2b−/+ were crossed to skeletal muscle-specific 
Mck-rtTA−/+ mice to produce Dox-inducible skeletal muscle-selective expression in the 
double transgenic offspring. (b) Anti-Myc immunoblot of Dox-induced DOC2B-Myc 
expression. Actin was used as the loading control. (c, d) Real-time PCR of Doc2b mRNA 
(relative to Hprt) in the skeletal muscle (c) and heart (d). (e) GLUT4 level in the 
sarcolemmal/t-tubule fractions of DOC2B-enriched (Dox+) and control (Dox−) muscle 
tissues with and without insulin stimulation. Ponceau S staining was used as the loading 
control. (f) Total GLUT4 level in the whole-muscle lysate of mice from the indicated 
genotypes with and without Dox treatment. Ponceau S staining at 50 kDa was used as the 
loading control. n=3; *p<0.05, **p<0.01 and ***p<0.001 as shown. Dashed vertical lines 
indicate splicing of lanes within the same gel exposure. Dox+, DOC2B-enriched; Dox−, 
control; Ins, insulin; K/O, knockout
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Fig. 4. 
DOC2B enrichment in skeletal muscle improves whole-body insulin sensitivity and glucose 
homeostasis. IPITT results for (a, b) female and (c, d) male DOC2B-enriched (Dox+) or 
control (Dox−) skmDoc2b-dTg mice. The mice were fasted for 6 h and AOC was quantified. 
IPGTT results for (e, f) female and (g, h) male DOC2B-enriched or control skmDoc2b-dTg 
mice. The mice were fasted for 6 h and AUC was quantified. Data are shown as mean ± 
SEM for 6–10 sets of mice. *p<0.05 and ***p<0.001 vs Dox− control. AOC, area over the 
curve. Dox−, SkmDoc2b-dTg mice without Dox induction; Dox+, SkmDoc2b-dTg mice with 
Dox induction
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Fig. 5. 
DOC2B enrichment in skeletal muscle prevents HFD-induced insulin resistance. (a) IPITT 
results for male DOC2B-enriched or control skmDoc2b-dTg mice fed 60% HFD or standard 
chow for 4 weeks. AOC was quantified. Body weight (b) and energy intake (c) over 4 weeks 
of dietary challenge. Data are shown as mean ± SEM for eight sets of mice. *p<0.05 vs 
chow control, or as otherwise shown; For (b, c) *p<0.05 by comparison across the time 
course using ANOVA. Chow Ctrl, control mice fed standard chow; HFD, control mice fed 
60% HFD; HFD+Dox, DOC2B-enriched skmDoc2b-dTg mice fed 60% HFD
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Fig. 6. 
Insulin stimulation phosphorylates DOC2B and enhances its interaction with KLC1. (a) 
DOC2B phosphorylation measured as anti-PY20 immunoreactivity after anti-Myc 
immunoprecipitation of DOC2B-Myc from the hindlimbs of mice injected i.p. with saline or 
insulin. Total DOC2B-Myc level was used as a control. (b) DOC2B phosphorylation in L6-
GLUT4-myc myoblasts after insulin or pervanadate treatment using a phosphorylated 
protein enrichment column followed by immunoblotting. GFP and DOC2B-GFP were 
detected using anti-GFP at 25 kDa and 75 kDa, respectively. INSR was used as a control for 
the action of insulin and pV. (c) Effect of pervanadate treatment on the DOC2B–KLC1 
interaction, measured using immunoprecipitation with GFP antibody-conjugated Sepharose 
beads and immunoblotting with antibodies to KLC1 at 68 kDa or GFP for DOC2B-GFP and 
GFP at 75 kDa and 25 kDa, respectively (n=3). (d) Detection of the DOC2B–KLC1 
interaction in L6-GLUT4-myc myoblasts after insulin stimulation for 0, 3 and 5 min using 
the immunoprecipitation strategy described in (c) (n=3). Data are shown as mean ± SEM. 
*p<0.05 vs control (without insulin in a, d; without pervanadate [NA] in c). Dashed vertical 
lines indicate splicing of lanes within the same gel exposure. IB, immunoblot; Ins, insulin; 
IP: immunoprecipitation; NA, no addition; pV, pervanadate
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Fig. 7. 
The C2AB domain of DOC2B confers the protective action of DOC2B against insulin 
resistance in L6 cells. (a) Domain structure of DOC2B. C2A and C2B are C2 domains. (b) 
PM GLUT4 level in control and InsRes L6-GLUT4-myc myoblasts under basal conditions 
(−) and after 100 nmol/l insulin stimulation for 20 min. The immunofluorescence intensity 
of cell-surface GLUT4 was normalised to the nucleic acid staining dye SYTO 60. The 
myoblasts were transfected with DOC2B-GFP, C2AB-GFP or control GFP plasmid DNAs 
prior to InsRes induction (n=3). Data are shown as mean ± SEM. *p<0.05 as shown. (c) A 
simulated structure showing the solvent accessibility and structural location of Y301 using 
PyMOL. The original structure file was extracted from PBD protein data bank (PDB number 
4LDC, https://www.rcsb.org/structure/4LDC) and the solvent accessibility was simulated 
using PyMOL (Schrödinger, New York, NY, USA; https://pymol.org/2/) according to the 
manufacturer’s instructions. a.a., amino acid; Ctrl, control
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Fig. 8. 
Y301F mutation in the C2B domain of DOC2B attenuates the DOC2B–KLC1 interaction 
and blocks the protective effects of DOC2B. (a) Phosphorylated DOC2B-GFP measured 
using anti-GFP immunoprecipitation followed by immunoblotting with anti-PY20. Total 
DOC2B-GFP in the immunoprecipitated and the input fraction are shown as controls. (b) 
Detection of KLC1–DOC2B association using anti-GFP immunoprecipitation followed by 
immunoblotting with antibodies to KLC1, and to GFP for detection of DOC2B-GFP-WT 
and DOC2B-GFP-Y301F proteins at 75 kDa (n=3). (c) PM GLUT4 level in myoblasts 
transfected to express WT DOC2B or the Y301F mutant. GLUT4 levels were measured 
under basal conditions (−) and after 100 nmol/l insulin stimulation for 20 min. The 
immunofluorescence intensity of cell-surface GLUT4 was normalised to the nucleic acid 
staining dye SYTO 60. (d) 2-DG uptake in myotubes transduced to express WT DOC2B or 
the Y301F mutant. The myotubes were incubated under InsRes conditions and 2-DG uptake 
was measured in response to insulin stimulation (100 nmol/l) (n=3); *p<0.05 and **p<0.01 
as shown. Dashed vertical lines indicate splicing of lanes within the same gel exposure. IB, 
immunoblot; Ins, insulin; IP, immunoprecipitation
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